Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Novartis
McKinsey
Dow
Express Scripts
Cantor Fitzgerald
Boehringer Ingelheim
Queensland Health
McKesson
Mallinckrodt

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,335,335

« Back to Dashboard

Which drugs does patent 6,335,335 protect, and when does it expire?


Patent 6,335,335 protects ISTALOL and is included in one NDA. There has been one Paragraph IV challenge on Istalol.

This patent has eight patent family members in seven countries.

Summary for Patent: 6,335,335

Title: Prolonged-action eye drop
Abstract:Eye drops containing a .beta.-blocker such as cartelol hydrochloride are improved in the penetration of the .beta.-blocker into the eye and the retention thereof in the eye tissues by the incorporation of a C.sub.3-7 fatty acid such as sorbic acid to the eye preparations.
Inventor(s): Higashiyama; Masayo (Kobe, JP), Ohtori; Akira (Kobe, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:09/802,860
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bausch And LombISTALOLtimolol maleateSOLUTION/DROPS;OPHTHALMIC021516-001Jun 4, 2004AT2RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,335,335

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-302802Nov 05, 1997
Japan10-250009Sep 03, 1998

Non-Orange Book Patents for Patent: 6,335,335

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,645,963 Prolonged-action eye drop► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,335,335

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2307303► Subscribe
China1124842► Subscribe
China1278162► Subscribe
Germany69839152► Subscribe
European Patent Office1029537► Subscribe
Spain2297894► Subscribe
Japan4377052► Subscribe
World Intellectual Property Organization (WIPO)9922715► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Boehringer Ingelheim
Cantor Fitzgerald
Fish and Richardson
Chubb
Dow
Baxter
Farmers Insurance
AstraZeneca
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot